Guest

Andrew Dudum

Organizations

Hims & Hers Healthfounder, ceo

Interviews

Hims & Hers CEO Andrew Dudum on telehealth's next act: personalized diagnostics, compounding, and $2B+ revenue

Mentions

Hims & Hers stock crashes 32% after Novo Nordisk terminates partnership over alleged GLP-1 knockoff sales

FDA moves to end Ozempic knockoffs, but Hims & Hers says it will keep selling compounded versions

Hims & Hers Super Bowl ad for compounded semaglutide ignites debate over IP, patient safety, and the GLP-1 gray market

Nate Bosshard opens YC Demo Day coverage with early-stage investing outlook